Kato Hideaki, Sosa Hiroko, Mori Masaaki, Kaneko Takeshi
Kansenshogaku Zasshi. 2015 Sep;89(5):559-66. doi: 10.11150/kansenshogakuzasshi.89.559.
Metronidazole is an antibiotic classically used against most anaerobic bacteria and protozoa. Because an intravenous form of metronidazole has recently entered the market, the use of this antibiotic is attracting renewed interest in many clinical settings in Japan. However, neurotoxicity is a major adverse event: in the central nervous system metronidazole-induced encephalopathy is a rare but serious condition. We performed a literature review of 34 cases including 2 of our cases, 25 from domestic conference abstracts, and 7 cases presented in full research papers. The mean patient age was 64.7 years. The conditions most commonly treated with metronidazole were brain abscess (35.3%), liver abscess (17.6%), and Clostridium difficile infection (14.7%). The most common predisposing conditions were liver dysfunction (26.5%), diabetes and other metabolic disorders (20.6%), and hematologic or solid organ malignancy (14.7%). The mean period of administration before the onset of encephalopathy symptoms was 61.3 days, and the mean total dose was 95.9g. The initial chief complaints were dysarthria (in 70.6% of the cases) and ataxia (61.8%); 82.4% of the cases were diagnosed on the basis of MRI (T2-weighted or FLAIR imaging). The key imaging finding was high intensity in the dentate nucleus bilaterally (82.4%). Stopping the metronidazole led to symptom remission within 8.5 days, but the MRI changes remained longer than the clinical symptoms. Two patients (6.0%) developed irreversible disturbance of consciousness. Although the mechanisms of this type of encephalopathy have not yet been elucidated, localized nerve-cell edema is likely caused by decreased metronidazole metabolism associated with liver and metabolic dysfunction. Careful observation for neurologic signs should be conducted during the treatment of brain abscesses associated with metronidazole administration, because patients with brain abscesses are naturally at high risk of metronidazole-induced encephalopathy.
甲硝唑是一种经典的抗生素,常用于对抗大多数厌氧菌和原生动物。由于静脉注射用甲硝唑最近已进入市场,这种抗生素的使用在日本的许多临床环境中重新引起了人们的兴趣。然而,神经毒性是一种主要的不良事件:在中枢神经系统中,甲硝唑诱发的脑病是一种罕见但严重的病症。我们对34例病例进行了文献综述,其中包括我们的2例病例、25例来自国内会议摘要的病例以及7例发表在完整研究论文中的病例。患者的平均年龄为64.7岁。最常使用甲硝唑治疗的病症是脑脓肿(35.3%)、肝脓肿(17.6%)和艰难梭菌感染(14.7%)。最常见的诱发因素是肝功能不全(26.5%)、糖尿病和其他代谢紊乱(20.6%)以及血液系统或实体器官恶性肿瘤(14.7%)。脑病症状出现前的平均给药期为61.3天,平均总剂量为95.9克。最初的主要主诉是构音障碍(70.6%的病例)和共济失调(61.8%);82.4%的病例是根据磁共振成像(T2加权或液体衰减反转恢复成像)诊断的。关键的影像学表现是双侧齿状核高强度(82.4%)。停用甲硝唑后,症状在8.5天内缓解,但磁共振成像的变化比临床症状持续的时间更长。两名患者(6.0%)出现了不可逆的意识障碍。虽然这种类型的脑病的机制尚未阐明,但局部神经细胞水肿可能是由与肝脏和代谢功能障碍相关的甲硝唑代谢减少引起的。在使用甲硝唑治疗脑脓肿期间,应仔细观察神经系统体征,因为脑脓肿患者自然处于甲硝唑诱发脑病的高风险中。